Get started
Author

Mary Ann Hardwicke

Observed names: Hardwicke, Mary, M A Hardwicke, M.A. Hardwicke, Mary Ann A. Hardwicke, Mary Ann Hardwicke
OpenAlex ID: A5002805151
Subtype and pathway specific responses to anticancer compounds in breast cancer
2011 · Laura M. Heiser, Anguraj Sadanandam, et al. · Proceedings of the National Academy of Sciences · 473
Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression
1992 · Irene L. Smith, Mary Ann Hardwicke, et al. · Virology · 275
The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection
1994 · M A Hardwicke, R M Sandri-Goldin · Journal of Virology · 191
Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers
2006 · Wenle Xia, John Bisi, et al. · Cancer Research · 153
The C-terminal repressor region of herpes simplex virus type 1 ICP27 is required for the redistribution of small nuclear ribonucleoprotein particles and splicing factor SC35; however, these alterations are not sufficient to inhibit host cell splicing
1995 · R M Sandri-Goldin, M K Hibbard, et al. · Journal of Virology · 136
Molecular Target Class Is Predictive of In vitro Response Profile
2010 · Joel Greshock, Kurtis E. Bachman, et al. · Cancer Research · 125
PDF
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
2009 · Mary Ann Hardwicke, Catherine A. Oleykowski, et al. · Molecular Cancer Therapeutics · 115
Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
2010 · Nicholas D. Adams, Jerry L. Adams, et al. · Journal of Medicinal Chemistry · 113
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
2014 · Mary Ann Hardwicke, Alan R Rendina, et al. · Nature Chemical Biology · 106
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
2015 · Hong Lin, Jin Zeng, et al. · ACS Medicinal Chemistry Letters · 89
The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule
1989 · M A Hardwicke, P J Vaughan, et al. · Journal of Virology · 84
Differential effects of nerve growth factor and dexamethasone on herpes simplex virus type 1 oriL- and oriS-dependent DNA replication in PC12 cells
1997 · M A Hardwicke, P A Schaffer · Journal of Virology · 57
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1
2009 · Kelly Anderson, Zhihong Lai, et al. · Biochemical Journal · 56
Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors
2012 · Robert M. Sanchez, Karl Erhard, et al. · Bioorganic & Medicinal Chemistry Letters · 54
Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors
2012 · Hong Lin, Karl Erhard, et al. · Bioorganic & Medicinal Chemistry Letters · 43
Mutations in the activation region of herpes simplex virus regulatory protein ICP27 can be trans dominant
1991 · I L Smith, R E Sekulovich, et al. · Journal of Virology · 40
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
2012 · Hong Lin, Mark J. Schulz, et al. · ACS Medicinal Chemistry Letters · 39
The herpes simplex virus immediate early protein ICP27 encodes a potential metal binding domain and binds zinc in vitro
1992 · Patrick J. Vaughan, Kelly J. Thibault, et al. · Virology · 37
Cloning and characterization of herpes simplex virus type 1 oriL: comparison of replication and protein-DNA complex formation by oriL and oriS
1995 · M A Hardwicke, P A Schaffer · Journal of Virology · 32
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
2016 · Zhi Hu, Jian-Hua Mao, et al. · Breast Cancer Research · 31
PDF
Promoter-independent activation of heterologous virus gene expression by the herpes simplex virus immediate-early protein ICP27
1992 · Caroline J. Chapman, Julian D. Harris, et al. · Virology · 26
Pharmacological inhibition of Aurora-A but not Aurora-B impairs interphase microtubule dynamics
2009 · Corinne Lorenzo, Qiaoyin Liao, et al. · Cell Cycle · 20
PDF
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916
2010 · Jesus R. Medina, Seth W. Grant, et al. · Bioorganic & Medicinal Chemistry Letters · 19
[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors
2013 · Hongyi Yu, Michael L. Moore, et al. · ACS Medicinal Chemistry Letters · 17
Properties of the novel herpes simplex virus type 1 origin binding protein, OBPC
1996 · K Baradaran, M A Hardwicke, et al. · Journal of Virology · 16
Works count: 60
Citation count: 2,380
H-index: 21
I10-index: 27
Year
Topic
Type